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Summary paragraph  102 
Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide1,2. Although 103 
58 genomic regions have been associated with CAD to date3-9, most of the heritability is unexplained9, 104 
indicating additional susceptibility loci await identification. An efficient discovery strategy may be 105 
larger-scale evaluation of promising associations suggested by genome-wide association studies 106 
(GWAS). Hence, we genotyped 56,309 participants using a targeted gene array derived from earlier 107 
GWAS results and meta-analysed results with 194,427 participants previously genotyped to give a 108 
total of 88,192 CAD cases and 162,544 controls.  We identified 25 new SNP-CAD-associations (P < 109 
5x10-8, in fixed effects meta-analysis) from 15 genomic regions, including SNPs in or near genes 110 
involved in cellular adhesion, leucocyte migration and atherosclerosis (PECAM1, rs1867624), 111 
coagulation and inflammation (PROCR, rs867186 [p.Ser219Gly]) and vascular smooth muscle cell 112 
differentiation (LMOD1, rs2820315). Correlation of these regions with cell type-specific gene 113 
expression and plasma protein levels shed light on potential novel disease mechanisms. 114 
 115 
 116 
 117 
  118 
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MAIN TEXT 119 
The CardioMetabochip is a genotyping array that contains 196,725 variants of confirmed or suspected 120 
relevance to cardiometabolic traits derived from earlier GWAS.10 A previous meta-analysis by the 121 
CARDIoGRAMplusC4D consortium of 79,138 SNPs common to the CardioMetabochip and GWAS 122 
arrays, identified 15 new loci associated with CAD3. Using the CardioMetabochip, we genotyped 123 
56,309 additional samples of European (EUR; ~52%), South Asian (SAS; ~23%), East Asian (EAS; 124 
~17%) and African American (AA; ~8%) ancestries (Supplementary Information; Supplementary 125 
Tables 1, 2, 3; Supplementary Fig. 1). The results from our association analyses of these additional 126 
samples were meta-analysed with those reported by CARDIoGRAMplusC4D at 79,070 SNPs in two 127 
fixed effects meta-analyses, one in EUR participants and a second across all four ancestries (Figure 1 128 
and 2). (Over-lapping samples were removed prior to meta-analysis [Methods]). A genome-wide 129 
significance threshold (P≤5x10-8 in the fixed effects meta-analysis) was adopted to minimise false 130 
positive findings. However, even at this strict P-value threshold, there is still a small chance of a 131 
false-positive result. The EUR fixed effects meta-analysis identified 15 SNPs associated with CAD at 132 
genome-wide significance (P<5x10-8) from nine distinct genomic regions that are not established 133 
CAD-associated loci (Table 1; Supplementary Table 4; Supplementary Fig. 2). An additional six 134 
distinct novel CAD-associated regions were identified in the all ancestries fixed effects meta-analysis 135 
(Table 1; Figure 2; Supplementary Table 4). In total, 15 novel CAD-associated genomic regions (25 136 
SNPs) were identified (Supplementary Fig. 3 and 4). The lead SNPs had at least nominal evidence of 137 
association (P<0.05) in either a fixed effects meta-analysis of the EUR studies with de novo 138 
genotyping, or in a fixed effects meta-analysis of all the studies with de novo genotyping 139 
(Supplementary Table 5, Supplementary Fig. 5). Within the CARDIoGRAMplusC4D results for these 140 
SNPs, there was no evidence of heterogeneity of effects (P≥0.10) and allele frequencies were 141 
consistent with our EUR studies (Supplementary Table 5). Tests for enrichment of CAD-associations 142 
within sets of genes11 and Ingenuity Pathway Analysis confirmed known CAD pathways 143 
(Supplementary Information; Supplementary Tables 6, 7, 8). 144 
 145 
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To prioritize candidate causal genes at the new loci, we defined regions encompassing the novel 146 
CAD-associated SNPs based on recombination rates (Supplementary Table 9) and cross referenced 147 
them with expression quantitative trait loci (eQTL) databases including GTEx12,  MuTHER13 and 148 
STARNET14 (Methods). Twelve of the 15 novel CAD-associated SNPs were identified as potential 149 
eQTLs in at least one tissue (P<5x10-8; Table 2, Supplementary Table 10). Haploreg analysis15 150 
(Methods) showed CAD-associated SNPs were enriched for H3K27ac enhancer marks (P < 5.1x10-4) 151 
in multiple heart related tissues (left ventricle, right atrium, aorta) in the EUR results and in one heart 152 
related tissue (right atrium) and liver in the all ancestry analyses (Supplementary Table 11). We next 153 
tested for protein quantitative trait loci (pQTL) in plasma on the aptamer-based Somalogic platform 154 
(Methods). Twenty-four proteins from the newly identified CAD regions were assayed and passed 155 
QC. Of our 15 novel CAD-associated SNPs, two associated with plasma protein abundance in trans: 156 
rs867186 (NP_006395.2:p.Ser219Gly), a missense variant in PROCR was a trans-pQTL for protein C 157 
(P=10-10, discussed below) and rs1050362 (NP_054722.2:p.Arg140=) a synonymous variant in 158 
DHX38 was a trans-pQTL for the apolipoprotein L1 (P=5.37x10-29; Methods) which is suggested to 159 
interact with HPR in the DHX38 region (string database).  160 
  161 
To further help prioritize candidate genes, we also queried the mouse genome informatics database to 162 
discover phenotypes resulting from mutations in the orthologous genes for all genes in our 15 CAD-163 
associated regions (Table 2). To understand the pathways by which our novel loci might be related to 164 
CAD risk, we examined the associations of the 15 novel CAD regions with a wide range of risk 165 
factors, molecular traits, and clinical disorders, using PhenoScanner16 (which encompasses the 166 
NHGRI-EBI GWAS catalogue and other genotype-phenotype databases).   167 
 168 
Six of our loci have previously been associated with known CAD risk factors, such as major lipids 169 
(PCNX3,17 C12orf43/HNF1A, SCARB1, DHX38)18 and blood pressure (GOSR2,19 PROCR20). The 170 
sentinel variants for the CAD and risk factor associations at PCNX3, GOSR2 and PROCR were the 171 
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same, implicating them in known biological pathways. Two correlated SNPs (r2=0.93, D’=1.0 in 1000 172 
genomes) rs11057830 and rs11057841 tag the CAD-association in the SCARB1 region (Table 1; 173 
Supplementary Table 4), a region reported previously to be associated with HDL (rs838876, β=-174 
0.049, P=7.33x10-33)18. A rare nonsynonymous variant rs74830677 (NP_005496.4:p.Pro376Leu) in 175 
SCARB1 also associated with high levels of high-density lipoprotein cholesterol (HDL-C)21. 176 
Conditional analyses showed that the CAD-association was independent of the common variant HDL 177 
association (Supplementary Information, Supplementary Fig. 6). We found the CAD SNPs and the 178 
common HDL-C SNP, rs838880 overlap enhancers active in primary liver tissue (Supplementary Fig. 179 
7). SCARB1 is highly expressed in liver and adrenal gland tissues (GTEx; Supplementary Fig. 7)12. 180 
These findings suggest that the discovered genetic variants most likely play a role in regulation of 181 
liver-restricted expression of SCARB1.  182 
The DHX38 region has previously been associated with increased total and LDL cholesterol18. Both 183 
CAD-associated SNPs in DHX38, rs1050362 (NP_054722.2:p.Arg140=) and rs2072142 (synonymous 184 
and intronic respectively; Table 1, Supplementary Table 4) are in LD but not strongly correlated with 185 
the previously reported cholesterol increasing SNP, intronic in HPR, rs2000999, (r2=0.41, D’=1 in 186 
1000 Genomes EUR). Deletions in the HP gene have recently been shown to drive the reported 187 
cholesterol association in this region22. The CAD SNPs are in strong LD with SNPs that increase 188 
haptoglobin levels23 (rs6499560, P=2.92x10-13, r2=0.97), and haptoglobin has been reported to be 189 
associated with increased CAD risk24. HP encodes an alpha-2-glycoprotein which is synthesised in the 190 
liver. It binds free haemoglobin and protects tissues from oxidative damage. Mouse models indicate 191 
the role of Hp with development of atherosclerosis25, where the underlying mechanism is disruption 192 
of the protective nature of the Hp protein against hemoglobin-induced injury of atherosclerotic 193 
plaque. While the CAD-associated SNPs are eQTLs (or in LD with eQTLs) for multiple genes in the 194 
region e.g. DHODH in aorta artery12 (rs1050362 A allele, β=0.41, P=1.4x10-9),  DHX38 in peripheral 195 
blood26, atherosclerotic aortic root14 (P<8x10-26; Table 2, Supplementary Table 10), the A allele at 196 
rs1050362 is also associated with increased expression of HP in left ventricle heart (β=0.535, 197 
P=8.71x10-10)12 and decreased expression of HP in whole blood (β=-0.27, P=1.22x10-10)12. While 198 
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there could be multiple causal genes in the region, together these findings suggest HP is a promising 199 
candidate gene.  200 
 201 
PROCR encodes the endothelial protein C receptor (EPCR). We found the G allele at rs867186 202 
(which codes for the glycine residue at p.Ser219Gly) in PROCR confers protection from CAD 203 
(OR[95%CI]=0.93[0.91-0.96]; Table 1, Supplementary Fig. 8). The same variant is also associated 204 
with increased circulating levels of soluble EPCR (which does not enhance protein C activation)27, 205 
increased levels of protein C28, increased factor VII levels29, and increased risk of venous 206 
thrombosis27. Consistent with these associations, the variant has also been demonstrated to render the 207 
EPCR more susceptible to proteolytic cleavage, resulting in increased shedding of membrane-bound 208 
EPCR from the endothelial surface30 causing elevated protein C levels in the circulation31. We found 209 
evidence of a second, independent CAD-association at rs6088590 (r2=0, D’=0.01 with rs867186 in 210 
1000G EUR samples; Supplementary Fig. 8), an intronic SNP in NCOA6 with the T allele conferring 211 
increased risk of CAD (conditional on rs867186, conditional P=1.14x10-5, OR[95% CI]=0.97[0.95-212 
0.98]). No additional SNPs were associated with CAD after conditioning on rs867186 and rs6088590 213 
(P>0.01).  214 
 215 
Five of the novel CAD regions identified in the current analysis include genes that encode proteins 216 
expressed in smooth muscle cells (LMOD1, SERPINH1, DDX59/CAMSAP2, TNS1, PECAM1)32,33. 217 
The CAD risk allele (T) of rs2820315, which is intronic in LMOD1, is associated with increased 218 
expression of LMOD1 in omental and subcutaneous adipose tissues13,34 (MuTHER, β=0.11, 219 
P=1.43x10-11). The protein is found in smooth muscle cells (SMC)32,33. In vitro and transgenic mouse 220 
studies demonstrate an essential requirement for CArG elements in the expression of LMOD1 through 221 
both serum response factor (SRF) and myocardin (MYOCD)35. Myocardin has emerged as an 222 
important molecular switch for the programs of SMC and cardiac myocyte differentiation36,37. The 223 
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CAD-associated SNP (or tag) is an eQTL for IPO9 in peripheral blood mononuclear cells38, however, 224 
given the prior biological evidence LMOD1 would make the most plausible candidate gene.  225 
 226 
rs1867624 is upstream of PECAM1, which encodes platelet/endothelial cell adhesion molecule 1, a 227 
protein found on platelet, monocyte and neutrophil surfaces. The C-allele is associated with reduced 228 
CAD risk (Table 1), increased expression of PECAM1 in peripheral blood mononuclear cells38 229 
(β=0.1199, P=1.38x10-107) and is in LD with rs2070784 and rs6504218 (D’=1.0, r2>0.8 in 1000G 230 
EUR samples), which are eQTL for PECAM1 in aortic endothelial cells (P=4.35x10-13) and stimulated 231 
CD14+ monocytes39 respectively (P<1.7x10-24; Supplementary Table 10)39. PECAM-1 has been 232 
implicated in the maintenance of vascular barrier integrity, breach of which is a sign of inflammatory 233 
response. Failure to restore barrier function contributes to the development of chronic inflammatory 234 
diseases such as atherosclerosis. PECAM-1 expressing endothelial cell monolayers have been shown 235 
to exhibit increased steady-state barrier function, as well as more rapid restoration of barrier integrity 236 
following thrombin-induced perturbation compared to PECAM-1 deficient cells40. Expression of 237 
PECAM-1 has been shown to be correlated with increased plaque burden in athero-susceptible 238 
regions of the aorta in mice41 and also with decreased atherosclerotic area in the aorta overall42. 239 
Together, these findings prioritise PECAM1 as a candidate causal gene for this CAD-associated 240 
region in humans.  241 
 242 
Of the 58 previously established CAD loci3-9, 47 were included on the CardioMetabochip. Forty-five 243 
regions were directionally concordant with the previous reports (two were neutral) and thirty-four of 244 
these 45 (42 SNPs) had at least nominal evidence of association in a fixed effects meta-analysis 245 
(P<0.05) in either our EUR or all ancestry studies with de novo genotyping (Supplementary Table 246 
12). Twenty-three of these formally replicated at a Bonferroni significance level P=0.05/47=0.001). 247 
PHACTR1, CXCL12 and COL4A1-COL4A2 had more statistical support of association (smaller P-248 
values despite fewer samples) in SAS compared with the other ancestries. The PHACTR1 SNP, 249 
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rs9349379, is ancestrally informative, as the A allele frequency ranges between 0.29 in the Taiwanese 250 
and 0.91 in African Americans (Supplementary Table 12). In contrast, the COL4A1-COL4A2 SNP, 251 
rs4773144, had similar allele frequencies across ancestries (EAF=0.56-0.62). The stronger effect size 252 
in SAS (OR[95%CI]=0.91[0.86-0.95] versus 0.98[0.95-1.02] in EUR, heterogeneity P=0.0042) could 253 
suggest gene-environment or gene-gene interactions at this locus. 254 
 255 
We have reported 15 novel CAD-associations, which, together with previous efforts, brings the total 256 
number of CAD-associated regions to 73. In addition to implicating atherosclerosis and traditional 257 
risk factors as mechanisms in the pathobiology of CAD, our discoveries highlight the potential 258 
importance of biological processes active in the arterial wall involving endothelial, smooth muscle 259 
and white blood cells and promote coronary atherogenesis.  260 
 261 
URLs 262 
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Figure Legends  420 
Figure 1 Schematic of the study design. The sample-size information is provided as number of 421 
cases/number of controls. Note, samples with de novo genotyping that were also in the 422 
CARDIoGRAMplusC4D study were removed prior to meta-analysis.∗ 1,826 CAD cases and 449 423 
controls from EPIC-CVD with de novo genotyping were also included in CARDIoGRAMplusC4D 424 
and were therefore excluded from the larger meta-analysis. The actual number of EUR individuals 425 
contributed to the meta-analysis of our studies with de novo genotyping and CARDIoGRAMplusC4D 426 
was 14,267 CAD cases and 16,167 controls.†3,704 CAD cases and 3,433 controls from PROMIS 427 
with de novo genotyping were also included in CARDIoGRAMplusC4D and were therefore excluded 428 
from the larger meta-analysis. The actual number of SAS samples contributed to the meta-analysis of 429 
our studies with de novo genotyping and CARDIoGRAMplusC4D was 3,950 CAD cases and 3,581 430 
controls. 431 
 432 
Figure 2 Plot showing the association of ~79,000 variants with CAD (-log10P-value) in up to 88,192 433 
cases and 162,544 controls from the all ancestry fixed effects meta-analysis. SNPs are ordered in 434 
physical position. No adjustments to P-values to account for multiple testing have been made. The 435 
outer track represents the chromosomal number. Blue dots represent known loci and red dots are the 436 
new loci identified in the current study. Each association peak is labeled with the name of the closest 437 
gene(s) to the sentinel SNP. GWAS significance (-log10(P) ~ 7.3). 438 
 439 
  440 
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Table 1 Newly identified CAD-associated genomic regions CAD-association results for the lead SNPs from the European and the all ancestry meta-analyses are reported. 441 
Note, SNP allele frequencies for each ancestry are provided in, Supplementary Table 5 and in Supplementary Fig. 3 for each of the studies with de novo genotyping. 442 
Closest gene(s) Variant/alleles Chr:Position (EA AF) European All Ancestries 
  OR [95% CI] P N OR [95%CI] P log10BF N 
ATP1B1 rs1892094C>T 1:169094459 (T 0.50) 0.96 [0.94-0.97] 3.99x10-8 217,782 0.96 [0.94-0.97] 2.25x10-8 6.33 243,623 
DDX59/CAMSAP2 rs6700559C>T 1:200646073 (T 0.47) 0.96 [0.94-0.97] 2.50x10-8 221,073 0.96 [0.95-0.97] 1.13x10-8 6.68 246,913 
LMOD1 rs2820315C>T 1:201872264 (T 0.30) 1.05 [1.03-1.07] 4.14x10-9 214,844 1.05 [1.03-1.07] 7.70x10-10 7.72 240,685 
TNS1a rs2571445G>A 2:218683154 (A 0.39) 1.04 [1.02-1.06] 3.58x10-6 194,254 1.05 [1.03-1.06] 4.55x10-10 8.41 220,047 
ARHGAP26 rs246600C>T 5:142516897 (T 0.48) 1.05 [1.03-1.06] 1.29x10-8 210,380 1.04 [1.03-1.06] 1.51x10-8 6.39 236,223 
PARP12 rs10237377G>T 7:139757136 (T 0.35) 0.95 [0.93-0.97] 1.70x10-7 181,559 0.95 [0.93-0.97] 1.75x10-8 6.32 207,399 
PCNX3 rs12801636G>A 11:65391317 (A 0.23) 0.95 [0.93-0.97] 1.00x10-7 211,152 0.95 [0.94-0.97] 9.71x10-9 6.64 236,985 
SERPINH1 rs590121G>T 11:75274150 (T 0.30) 1.05 [1.03-1.07] 1.54x10-8 207,426 1.04 [1.03-1.06] 9.32x10-8 5.80 233,249 
C12orf43/HNF1A rs2258287C>A  12:121454313 (A 0.34) 1.05 [1.03-1.06] 6.00x10-9 221,068 1.04 [1.03-1.06] 2.18x10-8 6.40 246,901 
SCARB1 rs11057830G>A 12:125307053 (A 0.16) 1.07 [1.05-1.10] 5.65x10-9 177,550 1.06 [1.04-1.09] 1.34x10-8 6.49 203,394 
OAZ2, RBPMS2 rs6494488A>G 15:65024204 (G 0.18) 0.95 [0.93-0.97] 1.43x10-6 205,410 0.95 [0.93-0.97] 2.09x10-8 6.41 228,578 
DHX38 rs1050362C>A 16:72130815 (A 0.38) 1.04 [1.03-1.06] 2.32x10-7 216,025 1.04 [1.03-1.06] 3.52x10-8 6.16 241,858 
GOSR2 rs17608766T>C 17:45013271 (C 0.14) 1.07 [1.04-1.09] 4.14x10-8 215,857 1.06 [1.04-1.09] 2.10x10-7 5.30 231,213 
PECAM1 rs1867624T>C 17:62387091 (C 0.39) 0.96 [0.94-0.97] 1.14x10-7 220,831 0.96 [0.95-0.97] 3.98x10-8 6.03 246,674 
PROCRa rs867186A>G 20:33764554 (G 0.11) 0.93 [0.91-0.96] 1.26x10-8 213,505 0.93 [0.91-0.96] 2.70x10-9 7.11 239,340 
aThese are nonsynonymous SNPs. 443 
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EA, Effect allele. AF, Effect allele frequency in Europeans. N, Number of individuals in the analysis. Log10BF, log base 10 of the Bayes factor obtained from the MANTRA 444 
analyses (log10BF>6 is considered significant). There was no convincing evidence of heterogeneity at the new CAD-associated SNPs, Phet ≥ 0.01. P-value for heterogeneity 445 
across meta-analysed datasets are provided in Supplementary Table 4 and I2 statistics in Supplementary Fig. 3. 446 
 447 
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Table 2 Summary of functional data implicating candidate causal genes in newly identified CAD regions. Genes in region, provides genes in the LD block containing 449 
the CAD-associated SNP.  Phenotype in murine model, lists the phenotype as provided in the mouse genome informatics database, genes are listed if the phenotype affects 450 
the cardiovascular system, inflammation   or liver function. eQTLs are listed  where the SNP or a proxy with r2> 0.9 are an eQTL for the listed gene in one of the following refs: 451 
12, 13, 26, 43, 44, 45, 46,38,47,48,14,49 (refer to Supplementary Table 10 for an extended listing where r2>0.8 between the CAD-associated SNP and the lead eQTL). Candidate genes are 452 
based on the most likely given the information ascertained on murine phenotype, eQTL, protein expression and any literature information described in the main text. Loci are 453 
further discussed in the Supplementary Information. 454 
SNP Genes in region Phenotype in murine model Cis-eQTLs with 
SNP (or proxy 
r2>0.9) 
Proteins expressed 
in SMC, heart, liver, 
blood+ 
Candidate 
causal 
gene(s) 
rs1892094C>T ATP1B1, BLZF1, CCDC181, F5, NME7, 
SELP, SLC19A2 
ATP1B1 (cardiovascular, homeostasis, mortality/aging, 
muscle) F5 (blood coagulation) SELP (cardiovascular, 
coagulation, inflammatory response) 
NME7*, ATP1B1* 
 
ATP1B1, NME7, SELP ATP1B1, NME7 
rs6700559C>T CAMSAP2, DDX59, KIF14  CAMSAP2*, DDX59* CAMSAP2, DDX59, KIF14 CAMSAP2, 
DDX59 
rs2820315C>T IPO9, LMOD1, NAV1, SHISA4, TIMM17A  LMOD1, IPO9* LMOD1 LMOD1 
rs2571445G>A CXCR2, RUFY4, TNS1 CXCR2 (increased IL6, abnormal interleukin level) TNS1* TNS1, RUFY4 TNS1 
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rs246600C>T ARHGAP26, FGF1 None
rs10237377G>T PARP12, TBXAS1 TBXAS1 (increased bleeding, decreased platelet 
aggregation) 
TBXAS1*  TBXAS1 
rs12801636G>A PCNX3, POLA2, RELA, RNASEH2C, 
SAC3D1, SCYL1, SIPA1, SLC22A20, 
SLC25A45, SNX15, SNX32, SPDYC, 
SSSCA1, SYVN1, TIGD3, TM7SF2, 
TMEM262, VPS51, ZFPL1, ZNHIT2 
CAPN1 (cardiovascular system), CDCA5 (decreased mean 
corpuscular volume),  CFL1 (cardiovascular system), 
EFEMP2 (cardiovascular), MUS81 (cardiovascular 
system), RELA (CVD  others), SCYL1 (small myocardial 
fiber),  
SIPA1* SIPA1  
rs590121G>T GDPD5, KLHL35, SERPINH1 SERPINH1 (hemorrhage) SERPINH1* SERPINH1 SERPINH1
rs2258287C>A SPPL3, HNF1A-AS1, HNF1A, C12orf43, 
OASL, P2RX7, P2RX4 
HNF1A (increased cholesterol, decreased liver function) 
P2RX4 (abnormal vascular endothelial cell physiology, 
abnormal vasodilation, abnormal common carotid artery 
morphology) 
 C12orf43, SPPL3, P2RX7, 
P2RX4 
 
rs11057830G>A SCARB1, UBC SCARB1 (increased susceptibility to atherosclerosis, 
reduced heart rate, abnormal lipoprotein metabolism 
abnormal vascular wound healing) 
None UBC SCARB1 
rs6494488A>G ANKDD1A, CSNK1G1, DAPK2, FAM96A, 
KIAA0101, OAZ2, PIF1, PLEKHO2, PPIB, 
PIF1 (abnormal telomere length) ANKDD1A*, 
RBPMS2*, TRIP4* 
TRIP4 TRIP4
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RBPMS2, SNX1, SNX22, TRIP4, ZNF609
rs1050362C>A AP1G1, ATXN1L, CALB2, CHST4, DHODH, 
DHX38, HP, HPR 
 HP (renal, development of atherosclerosis25) DHODH*, HP*, 
DHX38* 
HP, DHX38, DHODH HP 
rs17608766T>C ARL17A, CDC27, GOSR2, MYL4, WNT9B, 
WNT3 
 GOSR2* GOSR2   
rs1867624T>C DDX5, MILR1, PECAM1, POLG2, TEX2 DDX5 (abnormal vascular development), PECAM1 
(cardiovascular system, liver inflammation) 
PECAM1* PECAM1, TEX2 PECAM1
rs867186A>G RALY, EIF2S2, ASIP, AHCY, ITCH, 
DYNLRB1, MAP1LC3A,PIGU, HMGB3P1, 
GGT7, ACSS2, NCOA6,  GSS, MYH7B, 
TRPC4AP, EDEM2, PROCR, MMP24, EIF6 
ASIP (cardiovascular system), NCOA6 (cardiovascular 
system), PROCR (abnormal circulatiung C-reactive protein 
and fibrinogen levels; thrombosis/blood coagulation), 
PROCR*, EIF6*, 
ITGB4BP* 
EIF6, ITGB4BP PROCR
rs6088590 C>T PROCR*, GGT7*, 
MAP1LC3A*, 
ACSS2*, TRPC4AP* 
GGT7  
 455 
* indicates that the eQTL is identified in one of blood (including peripheral blood mononuclear cells) heart, aorta/coronary artery or live. Note the PCNX3 region also 456 
encompasses AP5B1, ARL2, CAPN1, CDC42EP2, CDCA5, CFL1, CTSW, DPF2, EFEMP2, EHBP1L1, FAM89B, FAU, FRMD8, KAT5, KCNK7, LTBP3, MAP3K11, MRPL49, 457 
MUS81, NAALADL1, OVOL1. The DHX38 region also encompasses, IST1, MARVELD3, PHLPP2, PKD1L3, PMFBP1, TAT, TXNL4B, ZFHX3, ZNF19, ZNF23, ZNF821. The 458 
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PROCR region also includes: FAM83C, UQCC1, GDF5, SPAG4, CEP250, C20orf173, ERGIC3, FER1L4, CPNE1, RBM12, NFS1, ROMO1, RBM39, SCAND1, CNBD2, 459 
EPB41L1, LINC00657, AAR2, DLGAP4460 
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Online Methods 461 
Study participants 462 
A full description of the component studies with de novo genotyping is given in the Supplementary 463 
Information and Supplementary Table 1. In brief, the European (EUR) studies comprised 16,093 464 
CAD cases and 16,616 controls from EPIC-CVD (a case-cohort study embedded in the pan-European 465 
EPIC prospective study), the Copenhagen City Heart Study (CCHS), the Copenhagen Ischemic Heart 466 
Disease Study (CIHDS) and the Copenhagen General Population Study (CGPS) all recruited within 467 
Copenhagen, Denmark. The South Asian (SAS) studies comprised up to 7,654 CAD cases and 7,014 468 
controls from the Pakistan Risk of Myocardial Infarction Study (PROMIS) a case-control study that 469 
recruited samples from 9 sites in Pakistan, and the Bangladesh Risk of Acute Vascular Events 470 
(BRAVE) study based in Dhaka, Bangladesh. The East Asian (EA) studies comprised 4,129 CAD 471 
cases and 6,369 controls recruited from 7 studies across Taiwan that collectively comprise the 472 
TAIwan metaboCHIp (TAICHI) Consortium. The African American (AA) studies comprised 2,100 473 
CAD cases and 5,746 controls from the Atherosclerosis Risk in Communities Study (ARIC), 474 
Women’s Health Initiative (WHI) and six studies from the Myocardial Infarction Genetics 475 
Consortium (MIGen).  476 
Ethical approval was obtained from the appropriate ethics committees and informed consent was 477 
obtained from all participants. 478 
 479 
Genotyping and quality control in studies with de novo genotyping  480 
Samples from EPIC-CVD, CCHS, CIHDS, CGPS, BRAVE and PROMIS were genotyped on a 481 
customised version of the Illumina CardioMetabochip (referred to as the “Metabochip+”, Illumina, 482 
San Diego, USA), in two Illumina-certified laboratories located in Cambridge, UK, and Copenhagen, 483 
Denmark, by technicians masked to the phenotypic status of samples. The remaining studies were 484 
genotyped using the standard CardioMetabochip10 in Hudson-Alpha and Cedars Sinai (TAICHI50, 485 
WHI, ARIC51) and the Broad Institute (MIGen). 486 
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Each collection was genotyped and underwent QC separately (Supplementary Tables 1 and 2). In 487 
brief, studies genotyped on the Metabochip+ had genotypes assigned using the Illumina GenCall 488 
software in Genome Studio. Samples were removed if they had a call rate < 0.97, average 489 
heterozygosity >±3 standard deviations away from the overall mean heterozygosity or their genotypic 490 
sex did not match their reported sex. One of each pair of duplicate samples and first degree relatives 491 
(assessed with a kinship co-efficient > 0.2) were removed.  492 
Across all studies, SNP exclusions were based on minor allele frequency (MAF) < 0.01, P < 1x10-6 493 
for Hardy Weinberg Equilibrium or call rate (CR) less than 0.97 (full details are given in 494 
Supplementary Table 2). These exclusions were also applied centrally to studies genotyped on the 495 
CardioMetabochip, namely the ARIC, WHI, MIGen and TAICHI studies. Principal component 496 
analysis (PCA) was applied to identify and remove ancestral outliers. More stringent thresholds were 497 
adopted for SNPs used in the PCA for TAICHI and those studies genotyped on the Metabochip+, 498 
namely, CR < 0.99, PHWE < 1x10-4 and MAF < 0.05. In addition, one of each pair of SNPs in LD (r2> 499 
0.2) was removed, as were variants in regions known to be associated with CAD.  500 
 501 
SNP association analyses and meta-analyses 502 
Statistical analyses were performed in R or PLINK 52 unless otherwise stated.  503 
We collected sufficient samples, to ensure the study was well powered to detect effect sizes in the 504 
range of OR=1.05-1.10 which have typically been reported for CAD. With 88,000 cases the study 505 
would have 88% power to detect an OR=1.05 for a SNP with MAF=0.2 at α=5x10-8, assuming a 506 
multiplicative model on the OR scale. For a lower MAF of 0.1 the study would have 0.93 power to 507 
detect OR=1.07 at α=5x10-8, assuming a multiplicative model. Power calculations were performed 508 
using Quanto. 509 
Association with CAD was assessed in studies with de novo genotyping from EUR, SAS, and EA, 510 
using the Genome-wide Efficient mixed model analysis (GEMMA) approach53. This model includes 511 
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both fixed effects and random effects of genetic inheritance. CAD (coded 0/1) was the outcome 512 
variable, up to five principal components and the test SNP, coded additively, were included as fixed 513 
effects. P-values from the score test are reported. The AA studies were analysed using a logistic 514 
model in PLINK, with CAD as the outcome variable and SNP coded additively as predictor. The 515 
covariates used by each study, including the number of principal components are reported in the 516 
Supplementary Information. Genomic inflation was at most 5% for any given study (Supplementary 517 
Table 3, Supplementary Fig. 1). A subset of the PROMIS study and EPIC-CVD consortium were 518 
contributed to the CARDIoGRAMplusC4D 2013 report. To avoid any overlap of individuals in our 519 
studies with those in CARDioGRAMplusC4D, two analyses of these two studies were performed. 520 
One analysis included all the samples. A second analysis of the PROMIS and EPIC-CVD studies was 521 
performed after excluding all samples that had been contributed to the CARDIoGRAMplusC4D study 522 
and before meta-analyzing our results with the results from CARDIoGRAMplusC4D consortium. The 523 
CARDIoGRAMplusC4D SNP association results were converted onto the plus strand of GRh37, 524 
checked for heterogeneity and checked to ensure allele frequencies were consistent with EUR 525 
populations. 526 
 527 
Fixed effects inverse variance weighted meta-analysis was used to combine results across studies in 528 
METAL54. Heterogeneity P-values and I2 values were calculated and any SNP with P < 0.0001 for 529 
heterogeneity was removed. We performed two meta-analyses, the first involved just the European 530 
studies with de novo genotyping and the CARDIoGRAMplusC4D results to minimize ancestral 531 
diversity. The second involved all studies with de novo genotyping and the CARDIoGRAMplusC4D 532 
results to maximize sample size and statistical power. Given the ancestral diversity of the component 533 
studies with de novo genotyping, we also implemented meta-analyses with MANTRA55, a meta-534 
analysis approach designed to handle trans-ethnic study designs. However, for our studies the data 535 
were broadly consistent with the results from METAL (Table 1, Supplementary Table 4) and we 536 
therefore primarily report the fixed effect meta-analysis.  537 
27 
 
Conditional association analyses 538 
Analyses to test for secondary association signals across seven regions with potential for independent 539 
signals were performed using GCTA56. GCTA implements a method for conducting conditional 540 
analyses using summary-level statistics (effect size, standard error, P-value, effective sample size) and 541 
LD information (r2) between SNPs estimated from a reference panel56. Conditional analyses were 542 
performed in CARDIoGRAMplusC4D, EUR, SAS, and EAS respectively and the results were 543 
combined using an inverse-variance-weighted fixed effects meta-analysis approach. The conditional 544 
analyses were not performed in AA, because the SNP-level case-control counts were not made 545 
available for ARIC, MIGen, and WHI. 1000Genome Phase3 v5 ethnic-specific reference panel was 546 
used to provide LD information (r2) for the conditioned SNPs and other SNPs in the test regions for 547 
each of the 3 ancestries considered in the analyses. As approximately 9% of CARDIoGRAMplusC4D 548 
samples were SAS and the remainder EUR, in order to calculate LD for this dataset, we sampled with 549 
replacement the genotypes of 50 individuals from the 1000Genome SAS reference panel and 550 
combined them with the genotypes of the 503 EUR individuals available in 1000 Genomes.  To 551 
identify SNPs that are associated with CAD independently of the lead SNP in the test region, the 552 
association of each SNP in the region was tested conditioning on the most significant SNP in the 553 
overall meta-analysis of EUR, SAS, EAS and CARIoGRAMplusC4D. The SNPs were identified as 554 
independent signals for a specific region, if the conditional P≤1x10-4. In each region, we performed 555 
several rounds of conditional analyses until the conditional P-values >1x10-4 for all SNPs in the 556 
region. 557 
eQTL and epigenetic analyses 558 
The MuTHER dataset contains gene expression data from 850 UK twins for 23,596 probes and 559 
2,029,988 (HapMap 2 imputed) SNPs. All cis–associated SNPs with FDR<1%, within each of the 14 560 
newly identified CAD regions (IMPUTE info score >0.8) were extracted from the MuTHER project 561 
dataset for each of the tissues, LCL (n=777), adipose (n=776) and skin (n=667).  562 
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The GTEx Project provides expression data from up to 449 individuals for 52,576 genes annotated in 563 
Gencode v12 (including pseudo genes) and 6,820,472 genotyped SNPs (using the Human Omni5-564 
Quad array).  565 
From each resource, we report eQTL signals, which reach the resource-specific thresholds for 566 
significance described above, for SNPs that are in LD (r2>0.8) with our sentinel SNP. 567 
In addition to the publicly available MuTHER and GTeX databases imputed to HapMap and 568 
1000Genomes, respectively, we used a curated database of over 100 distinct eQTL datasets to 569 
determine whether our lead CAD-associated SNPs or SNPs in high LD with them (r2 > 0.8 in 570 
Europeans from HapMap or 1000G) were associated with the expression of one or more nearby genes 571 
in cis57.  Our collated eQTL datasets meet criteria for statistical thresholds for SNP-gene transcript 572 
associations as described in the original studies. 57 In total, more than 30 different cells/tissues were 573 
queried including, circulating white blood cells of various types, liver, adipose, skin, brain, breast, 574 
heart and lung tissues.   Complete details of the datasets and tissues queried in the current work can be 575 
found in the Supplement Information and Supplementary Table 10, and a general overview of a subset 576 
of over 50 eQTL studies has been published57.  We first identified all sets of eQTLs in perfect LD (r2 577 
=1 among Europeans in HapMap or 1000G) with each other for each unique combination of study, 578 
tissue, and transcript. We then determined whether any of these sets of eQTL were either in perfect (r2 579 
= 1) or high LD (1>r2> 0.8) with our lead CAD SNP (Supplementary Table 10). 580 
We required that any eQTL had P<5x10-8 for association with expression levels to be included in the 581 
eQTL tables. 582 
 583 
We examined chromatin state maps of 23 relevant primary cell types and tissues. Chromatin states are 584 
defined as spatially coherent and biologically meaningful combinations of specific chromatin marks. 585 
These are computed by exploiting the correlation of such marks, including DNA methylation, 586 
chromatin accessibility, and several histone modifications58,59. 587 
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 588 
pQTL analyses 589 
We conducted plasma protein assays in 3,301 healthy blood donors from the INTERVAL study60 who 590 
had all been genotyped on the Affymetrix Axiom UK Biobank genotyping array and imputed to a 591 
combined 1000Genomes + UK10K haplotype reference panel61. Proteins were assayed using the 592 
SomaLogic SomaScan platform, which uses high-specificity aptamer-binding to provide relative 593 
protein abundances. Proteins passing stringent QC (e.g. coefficient of variation<20%) were log 594 
transformed and age, sex, duration between venepuncture and sample processing and the first 3 595 
principal components of genetic ancestry were regressed out. Residuals were then rank-inverse 596 
normalized before genomewide association testing using an additive model accounting for imputation 597 
uncertainty.  598 
 599 
Enrichment analyses 600 
Ingenuity pathway analyses 601 
We used the Core Analysis' function in the Ingenuity Pathway Analysis (IPA) software (Ingenuity 602 
Systems, Redwood City) to identify canonical pathways enriched with one or more SNPs with a low 603 
P-value in the all ancestry meta-analysis.   604 
Modified MAGENTA 605 
Given the Metabochip comprises a select set of SNPs and lacks complete genomic coverage10, 606 
MAGENTA, which assumes random sampling of variants from across the genome, could not be 607 
directly implemented. Therefore a modified version of MAGENTA involving a hypergeometric test to 608 
account for the chip design was used to test for pathways that were enriched with CAD-associated 609 
variants11. This approach requires defining two sets of variants; a null set of variants that are not 610 
associated with CAD and a set that are associated with CAD, referred to as the “associated set”. 611 
Multiple variants can map to the same gene and still be included in the test. SNPs in LD were pruned 612 
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out of the association results such that r2 < 0.2 for all pairs of SNPs (based on 1,000 Genomes Project 613 
data62; Supplementary Table 6) prior to implementation of the modified MAGENTA. The null set was 614 
defined as the 1,000 remaining QT interval SNPs with the largest P-values (least evidence) for 615 
association with CAD. The associated set was defined as variants (after LD pruning) that showed 616 
evidence of association P < 1x10-6. This approach was adopted to select the null and associated sets so 617 
as to limit the number of variants included in the hypergeometric cumulative mass function, as a large 618 
number of variants results in an intractable calculation for the binomial coefficients. The observed P-619 
value from the hypergeometric test is compared to the P-values obtained from 10,000 random sets to 620 
compute an empirical enrichment P-value. 621 
Haploreg: H3K27ac-based tissue enrichment analysis 622 
The associated set as defined for MAGENTA was used for Haploreg analyses and compared to a 623 
background set of 12,000 SNPs previously associated with any trait at P<1x10-5 (taken from sources 624 
such as NHGRI-EBI GWAS catalogue). Using data from HaploReg15 we counted the number of SNPs 625 
with an H3K27ac annotation, or in high LD (r2 > 0.8 from the SNiPA63 EUR 1000 Genomes maps) 626 
with a SNP with an H3K27ac annotation. The significance of the enrichment in H3K27ac marks from 627 
a particular tissue was determined by comparing the fraction of associated SNPs with that mark, to the 628 
fraction of background SNPs with that same mark. A hypergeometric test was used to assign a P-629 
value to the enrichment. 630 
 631 
Data availability 632 
The full set of results data from the trans-ancestry meta-analysis and the EUR meta-analysis from this 633 
report is available through www.phenoscanner.medschl.cam.ac.uk upon publication. 634 
  635 
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15 novel CAD loci
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